Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis

Ignacio, Katrina Hannah D.; Espiritu, Adrian I.; Diestro, Jose Danilo Bengzon; Chan, Kevin Ivan P.; Dmytriw, Adam A

doi:10.1007/s10072-021-05193-3

Cited by 13 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aspirin modifies both NF-κB signaling and COX-2 expression ( 116 ), and has been shown to have therapeutic effects in several tumors with high COX-2 levels ( 117 , 118 ). Although some studies have shown that aspirin may halt VS growth ( 119 , 120 ), the latest meta-analysis disproved this viewpoint ( 121 ).…”

Section: Resultsmentioning

confidence: 99%

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

et al. 2021

View full text Add to dashboard Cite

Vestibular schwannomas (VSs, also known as acoustic neuromas) are relatively rare benign brain tumors stem from the Schwann cells of the eighth cranial nerve. Tumor growth is the paramount factor for neurosurgeons to decide whether to choose aggressive treatment approach or careful follow-up with regular magnetic resonance imaging (MRI), as surgery and radiation can introduce significant trauma and affect neurological function, while tumor enlargement during long-term follow-up will compress the adjacent nerves and tissues, causing progressive hearing loss, tinnitus and vertigo. Recently, with the deepening research of VS biology, some proteins that regulate merlin conformation changes, inflammatory cytokines, miRNAs, tissue proteins and cerebrospinal fluid (CSF) components have been proposed to be closely related to tumor volume increase. In this review, we discuss advances in the study of biomarkers that associated with VS growth, providing a reference for exploring the growth course of VS and determining the optimal treatment strategy for each patient.

show abstract

Section: Resultsmentioning

confidence: 99%

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Crizotinib, AR-42 (OSU-HDAC42), everolimus, selumetinib (MEK 1/2 inhibitor), and tanezumab (a monoclonal antibody against nerve growth factor as a treatment for pain) are being evaluated in the trials. A previous meta-analysis suggests that there is insufficient evidence to recommend aspirin usage in patients with VS [ 77 , 78 ]. High-quality trials are warranted to determine the efficacy of aspirin in reducing VS growth (NCT03079999).…”

Section: Ongoing Clinical Trialsmentioning

confidence: 99%

A Critical Overview of Targeted Therapies for Vestibular Schwannoma

Tamura

Toda

2022

IJMS

View full text Add to dashboard Cite

Vestibular schwannoma (VS) is a benign tumor that originates from Schwann cells in the vestibular component. Surgical treatment for VS has gradually declined over the past few decades, especially for small tumors. Gamma knife radiosurgery has become an accepted treatment for VS, with a high rate of tumor control. For neurofibromatosis type 2 (NF2)-associated VS resistant to radiotherapy, vascular endothelial growth factor (VEGF)-A/VEGF receptor (VEGFR)-targeted therapy (e.g., bevacizumab) may become the first-line therapy. Recently, a clinical trial using a VEGFR1/2 peptide vaccine was also conducted in patients with progressive NF2-associated schwannomas, which was the first immunotherapeutic approach for NF2 patients. Targeted therapies for the gene product of SH3PXD2A-HTRA1 fusion may be effective for sporadic VS. Several protein kinase inhibitors could be supportive to prevent tumor progression because merlin inhibits signaling by tyrosine receptor kinases and the activation of downstream pathways, including the Ras/Raf/MEK/ERK and PI3K/Akt/mTORC1 pathways. Tumor-microenvironment-targeted therapy may be supportive for the mainstays of management. The tumor-associated macrophage is the major component of immunosuppressive cells in schwannomas. Here, we present a critical overview of targeted therapies for VS. Multimodal therapy is required to manage patients with refractory VS.

show abstract

“…Initial retrospective analysis of patients with sporadic vestibular schwannomas on aspirin for other indications indicated slower growth rates for those on aspirin [ 121 ]. More recent retrospective studies have not supported this correlation, and currently compelling data to recommend aspirin therapy for patients have not been reported [ 122 , 123 ]. To better define a potential role for aspirin, a phase 2 clinical trial for both NF2 and sporadic tumors is currently ongoing (NCT03079999).…”

Section: Neurofibromatosis Typementioning

confidence: 99%

Targeted Therapies for the Neurofibromatoses

Sanchez

Bui

Klesse

2021

Cancers

View full text Add to dashboard Cite

Over the past several years, management of the tumors associated with the neurofibromatoses has been recognized to often require approaches that are distinct from their spontaneous counterparts. Focus has shifted to therapy aimed at minimizing symptoms given the risks of persistent, multiple tumors and new tumor growth. In this review, we will highlight the translation of preclinical data to therapeutic trials for patients with neurofibromatosis, particularly neurofibromatosis type 1 and neurofibromatosis type 2. Successful inhibition of MEK for patients with neurofibromatosis type 1 and progressive optic pathway gliomas or plexiform neurofibromas has been a significant advancement in patient care. Similar success for the malignant NF1 tumors, such as high-grade gliomas and malignant peripheral nerve sheath tumors, has not yet been achieved; nor has significant progress been made for patients with either neurofibromatosis type 2 or schwannomatosis, although efforts are ongoing.

show abstract

Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis

Cited by 13 publications

References 13 publications

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects

A Critical Overview of Targeted Therapies for Vestibular Schwannoma

Targeted Therapies for the Neurofibromatoses

Contact Info

Product

Resources

About